We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RIASTAP CSL Behring (Australia) Pty Ltd
Product name
RIASTAP
Sponsor
Accepted date
Nov-2025
Active ingredients
Fibrinogen
Proposed indication
Riastap (fibrinogen) supplementation is proposed as a treatment to stop bleeding in people who do not have enough fibrinogen, a protein needed for blood to clot.
Application type
C (new indication)
Publication date
Nov-2025